The Hepatocellular Carcinoma (HCC) Laboratory is part of the Mount Sinai Liver cancer Program which leads the HCC Genomic Consortium. The Consortium, led by Josep Llovet, MD, conducts translational research in liver cancer.

• HCC International Consortium: Tissue bank collection and genomic studies.

• Todd Golub (Harvard, USA)
• Vincenzo Mazzaferro (INT, Italy)
• Lars Zender (U. Hannover, Germany)
• Jordi Bruix (Barcelona)

• Heptromic Consortium, Genomic predictors and oncogenic drivers in hepatocellular carcinoma.

• Manel Esteller (IDIBELL, Spain)
• Jessica Zucman-Rossi (INSERM, France)
• Vincenzo Mazzaferro (INT, Italy)
• Lars Zender (U. Hannover, Germany)
• Diagenode, Belgium

• FGFR2 fusions and pathogenesis of intrahepatic cholangiocarcinoma.

• Nabeel Bardeesy (Massachusetts General Hospital).

• Gene signatures defining cirrhotic patients at high risk of death.

• Massimo Colombo (Ospedale Maggiore Policlinico, Italy)
• Nanostring (USA).

• Other collaborations:
  • Fibrollamelar HCC Consortium – Seven US and European centers
  • miRNA and HCC – Russell (University of Washington, Seattle)
  • Experimental animal models in HCC – Largaespada (Mason University, Minnesota)
  • Oncogenic drivers in hepatoblastoma – Armengol (Institut GTiP, Barcelona)
  • Biomarkers of HCC survival after transplantation – Rakela (Mayo Clinic, USA)
  • Extrahepatic cholangiocarcinoma Consortium- Seven US and and European centers